Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cell. 2013 Aug 29;154(5):1151-61. doi: 10.1016/j.cell.2013.08.003.

An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules.

Author information

  • 1The Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.

Abstract

The high rate of clinical response to protein-kinase-targeting drugs matched to cancer patients with specific genomic alterations has prompted efforts to use cancer cell line (CCL) profiling to identify additional biomarkers of small-molecule sensitivities. We have quantitatively measured the sensitivity of 242 genomically characterized CCLs to an Informer Set of 354 small molecules that target many nodes in cell circuitry, uncovering protein dependencies that: (1) associate with specific cancer-genomic alterations and (2) can be targeted by small molecules. We have created the Cancer Therapeutics Response Portal (http://www.broadinstitute.org/ctrp) to enable users to correlate genetic features to sensitivity in individual lineages and control for confounding factors of CCL profiling. We report a candidate dependency, associating activating mutations in the oncogene β-catenin with sensitivity to the Bcl-2 family antagonist, navitoclax. The resource can be used to develop novel therapeutic hypotheses and to accelerate discovery of drugs matched to patients by their cancer genotype and lineage.

Copyright © 2013 Elsevier Inc. All rights reserved.

PMID:
23993102
[PubMed - indexed for MEDLINE]
PMCID:
PMC3954635
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk